Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Recombinant FVIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years of Age With Severe Hemophilia A

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02615691

Recruitment Status : Recruiting

First Posted : November 26, 2015

Last Update Posted : July 27, 2020

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Takeda ( Baxalta now part of Shire )

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	June 29, 2023
Estimated Study Completion Date :	June 29, 2023

To Top